Ted Skolarus to Aged
This is a "connection" page, showing publications Ted Skolarus has written about Aged.
Connection Strength
1.990
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
Score: 0.070
-
Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities. JCO Oncol Pract. 2023 05; 19(5):e763-e772.
Score: 0.063
-
Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology. 2020 08; 142:99-105.
Score: 0.053
-
Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. Urol Oncol. 2020 04; 38(4):255-261.
Score: 0.051
-
Association between PSA values and surveillance quality after prostate cancer surgery. Cancer Med. 2019 12; 8(18):7903-7912.
Score: 0.051
-
Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 11 01; 2(11):e1916008.
Score: 0.051
-
Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. J Clin Oncol. 2019 05 20; 37(15):1326-1335.
Score: 0.049
-
Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU Int. 2019 07; 124(1):55-61.
Score: 0.047
-
Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. Cancer. 2018 10 15; 124(20):3971-3974.
Score: 0.047
-
The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer. BJU Int. 2018 04; 121(4):558-564.
Score: 0.044
-
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
Score: 0.043
-
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials. 2017 04 18; 18(1):181.
Score: 0.043
-
No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. Urology. 2017 06; 104:77-83.
Score: 0.042
-
Variation in readmission expenditures after high-risk surgery. J Surg Res. 2017 06 01; 213:60-68.
Score: 0.042
-
Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. Urology. 2017 06; 104:131-136.
Score: 0.042
-
Treatment of ureteral anastomotic strictures with reimplantation and survival after cystectomy and urinary diversion. Urol Oncol. 2017 01; 35(1):33.e1-33.e9.
Score: 0.041
-
The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. Eur Urol Focus. 2018 09; 4(5):711-717.
Score: 0.040
-
Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016 09; 118(3):372-8.
Score: 0.038
-
Understanding hospital readmission intensity after radical cystectomy. J Urol. 2015 May; 193(5):1500-6.
Score: 0.036
-
Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May 01; 120(9):1409-16.
Score: 0.034
-
Quality of prostate cancer care among rural men in the Veterans Health Administration. Cancer. 2013 Oct 15; 119(20):3629-35.
Score: 0.033
-
Monitoring quality of life among prostate cancer survivors: the feasibility of automated telephone assessment. Urology. 2012 Nov; 80(5):1021-6.
Score: 0.031
-
Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
Score: 0.029
-
Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality. Cancer. 2012 Jun 01; 118(11):2837-45.
Score: 0.029
-
Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013 Aug; 31(6):727-32.
Score: 0.029
-
Understanding early functional recovery after robotic prostatectomy. Surg Innov. 2012 Mar; 19(1):5-10.
Score: 0.028
-
The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol. 2010 Dec; 184(6):2279-84.
Score: 0.027
-
Does robotic technology mitigate the challenges of large prostate size? Urology. 2010 Nov; 76(5):1117-21.
Score: 0.027
-
The economic burden of prostate cancer survivorship care. J Urol. 2010 Aug; 184(2):532-8.
Score: 0.026
-
Regional differences in early stage bladder cancer care and outcomes. Urology. 2010 Aug; 76(2):391-6.
Score: 0.026
-
Effect of reclassification on the incidence of benign and malignant renal tumors. J Urol. 2010 Feb; 183(2):455-8.
Score: 0.026
-
Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg. 2009 Aug; 209(2):248-53.
Score: 0.025
-
The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 2008 Feb; 179(2):439-43; discussion 443-4.
Score: 0.022
-
Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study. Breast Cancer Res. 2024 Dec 03; 26(1):176.
Score: 0.018
-
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
Score: 0.017
-
Utilization and Timing of Cystoscopy for Hematuria Evaluation by Advanced Practice Providers and Urologists. Urology. 2024 Jun; 188:80-86.
Score: 0.017
-
Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study. Cancer Med. 2024 Jan; 13(1):e6847.
Score: 0.017
-
Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System. JCO Oncol Pract. 2024 01; 20(1):59-68.
Score: 0.017
-
Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice. J Urol. 2023 Nov; 210(5):771-777.
Score: 0.016
-
Industry Payments to Urologists and Urologic Advanced Practice Providers in 2021. Urology. 2023 10; 180:121-129.
Score: 0.016
-
Evaluation of emergency department treat-and-release encounters after major gastrointestinal surgery. J Surg Oncol. 2023 Aug; 128(2):402-408.
Score: 0.016
-
Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. J Urol. 2022 09; 208(3):600-608.
Score: 0.015
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
Score: 0.015
-
Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology. 2021 09; 155:70-76.
Score: 0.014
-
Understanding Active Surveillance for Prostate Cancer. JCO Oncol Pract. 2021 11; 17(11):e1678-e1687.
Score: 0.014
-
Variations in Persistent Use of Low-Value Breast Cancer Surgery. JAMA Surg. 2021 04 01; 156(4):353-362.
Score: 0.014
-
Aligning Urology Residency Training With Real-World Workforce Needs. J Surg Educ. 2021 May-Jun; 78(3):820-827.
Score: 0.014
-
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
Score: 0.013
-
The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. Urology. 2020 11; 145:106-112.
Score: 0.013
-
Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urol Oncol. 2020 09; 38(9):734.e1-734.e10.
Score: 0.013
-
Resurrecting immortal-time bias in the study of readmissions. Health Serv Res. 2020 04; 55(2):273-276.
Score: 0.013
-
Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 06; 18(3):201-209.e2.
Score: 0.013
-
Implications of Cystectomy Travel Distance for Hospital Readmission and Survival. Clin Genitourin Cancer. 2019 12; 17(6):e1171-e1180.
Score: 0.012
-
Characterising 'bounce-back' readmissions after radical cystectomy. BJU Int. 2019 12; 124(6):955-961.
Score: 0.012
-
External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. J Urol. 2019 09; 202(3):518-524.
Score: 0.012
-
Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Ann Surg. 2019 05; 269(5):873-878.
Score: 0.012
-
Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2019 07; 37(7):462-469.
Score: 0.012
-
Urologist Practice Structure and Spending for Prostate Cancer Care. Urology. 2019 Aug; 130:65-71.
Score: 0.012
-
Role of Post-Acute Care on Hospital Readmission After High-Risk Surgery. J Surg Res. 2019 02; 234:116-122.
Score: 0.012
-
Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Cancer. 2018 08; 124(16):3364-3371.
Score: 0.012
-
Predictors and Cost of Readmission in Total Knee Arthroplasty. J Arthroplasty. 2018 09; 33(9):2759-2763.
Score: 0.011
-
Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology. 2018 06; 116:68-75.
Score: 0.011
-
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018 09; 200(3):541-548.
Score: 0.011
-
Association of the Hospital Readmissions Reduction Program With Surgical Readmissions. JAMA Surg. 2018 03 01; 153(3):243-250.
Score: 0.011
-
Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386.
Score: 0.011
-
Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. Cancer. 2018 02 01; 124(3):563-570.
Score: 0.011
-
Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. Eur Urol. 2018 04; 73(4):491-498.
Score: 0.011
-
Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Aff (Millwood). 2017 01 01; 36(1):108-115.
Score: 0.010
-
Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. Urology. 2017 04; 102:92-99.
Score: 0.010
-
Health Care Integration and Quality among Men with Prostate Cancer. J Urol. 2017 01; 197(1):55-60.
Score: 0.010
-
Negative information-seeking experiences of long-term prostate cancer survivors. J Cancer Surviv. 2016 12; 10(6):1089-1095.
Score: 0.010
-
Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
Score: 0.010
-
A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. J Urol. 2016 May; 195(5):1362-1367.
Score: 0.010
-
Expectant management of veterans with early-stage prostate cancer. Cancer. 2016 Feb 15; 122(4):626-33.
Score: 0.010
-
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84.
Score: 0.009
-
Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics. Urology. 2015 Aug; 86(2):255-60.
Score: 0.009
-
Reducing PSA-Based Prostate Cancer Screening in Men Aged?75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support. J Gen Intern Med. 2015 Aug; 30(8):1133-9.
Score: 0.009
-
Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8.
Score: 0.009
-
Exploring the role of the partner in couples' sexual recovery after surgery for prostate cancer. Support Care Cancer. 2014 Sep; 22(9):2509-15.
Score: 0.009
-
Adherence to performance measures and outcomes among men treated for prostate cancer. J Urol. 2014 Sep; 192(3):743-8.
Score: 0.009
-
Validating electronic cancer quality measures at Veterans Health Administration. Am J Manag Care. 2014; 20(12):1041-7.
Score: 0.008
-
Regional variation in quality of prostate cancer care. J Urol. 2014 Apr; 191(4):957-62.
Score: 0.008
-
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013 Jun 26; 309(24):2587-95.
Score: 0.008
-
Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013 Nov; 190(5):1715-20.
Score: 0.008
-
Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology. 2012 Dec; 80(6):1236-42.
Score: 0.008
-
Certificate of need legislation and the dissemination of robotic surgery for prostate cancer. J Urol. 2013 Jan; 189(1):80-5.
Score: 0.008
-
Hospitalization trends after prostate and bladder surgery: implications of potential payment reforms. J Urol. 2013 Jan; 189(1):59-65.
Score: 0.008
-
Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. Urology. 2012 Nov; 80(5):1015-20.
Score: 0.008
-
Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. 2014 Jan; 65(1):162-8.
Score: 0.008
-
Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood). 2012 Apr; 31(4):750-9.
Score: 0.007
-
Identifying better practices for early-stage bladder cancer. Med Care. 2011 Dec; 49(12):1112-7.
Score: 0.007
-
Understanding prostate cancer spending growth among Medicare beneficiaries. Urology. 2011 Feb; 77(2):326-31.
Score: 0.007
-
Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology. 2011 Feb; 77(2):385-90.
Score: 0.007
-
Delays in diagnosis and bladder cancer mortality. Cancer. 2010 Nov 15; 116(22):5235-42.
Score: 0.007
-
Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol. 2010 Mar; 183(3):909-14.
Score: 0.006
-
The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol. 2011 Nov-Dec; 29(6):738-44.
Score: 0.006